News und Analysen

You might think that the stock market would be really quiet during the holidays. After all, many investors are on vacation and take a break from buying and selling stocks. Interestingly, though, the

It's now a new ballgame for CRISPR Therapeutics (NASDAQ: CRSP). The company, along with its big partner, Vertex Pharmaceuticals (NASDAQ: VRTX), won U.S. regulatory approval for Casgevy (exa-cel) in

CRISPR Therapeutics (NASDAQ: CRSP) received great news last week. Its gene-editing therapy, which it has been developing with Vertex Pharmaceuticals, obtained approval from the Food and Drug

Don't have a lot of time to follow stocks and want some safe options for your portfolio? Three stocks that are big names within their respective industries and that can make for excellent long-term

Earlier in the pandemic, coronavirus products boosted the revenue and the stock prices of companies selling those products. But these days, those products actually have done just the opposite

You shouldn't have to keep a close eye on your investments. If you find solid stocks to buy, you can leave them in your portfolio and simply wait for their operations to grow and become larger over

When dividend stocks crash in value, that sends their yields up in the opposite direction. But there can be danger for investors who load up on a stock just because its yield is high.

Before buying

Pfizer (NYSE: PFE) was a top performer when the U.S. government was shoveling COVID-related revenue in its direction. Unfortunately, the past year hasn't been nearly as kind. The former high-flying

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are up by more than 11% headed into the latter half of Wednesday's trading session, catapulted higher by the promising results achieved in a mid-stage

Shares of Pfizer (NYSE: PFE) were sinking 8.3% lower as of 11:25 a.m. ET on Wednesday. The sharp sell-off came after the drugmaker provided its guidance for full-year 2024.

Pfizer expects 2024

The human genome project, which was completed in 2003, marked a milestone for biotechnology. It opened the door for the creation of hundreds of medicines based on biology, which have improved the

The stock market looked ready to keep climbing early Wednesday, even as investors were largely in wait-and-see mode during the last day of the Federal Reserve's current monetary policy meeting

Outperforming the benchmark S&P 500 index over a long period is a formidable challenge. This task becomes even more daunting when choosing stocks from the healthcare sector, where the competitive

With AbbVie (NYSE: ABBV) reporting on Nov. 30 that it plans to acquire ImmunoGen, (NASDAQ: IMGN) a biotech developing antibody-drug conjugate (ADC) therapies for various cancers, it's clear that the

Intellia Therapeutics (NASDAQ: NTLA) and CRISPR Therapeutics (NASDAQ: CRSP) have one big thing in common: They both specialize in the hot area of gene editing, or the repairing of faulty genes

The stock market has climbed this year, but that doesn't mean the bargains are over. Many stocks missed out on the rally even though their long-term outlooks remain solid. And these are the stocks

Shares of Cigna Group (NYSE: CI) were up 16.6% as of 1:30 p.m. ET Monday after the health insurance giant reportedly called off its potential acquisition Humana and announced a $10 billion buyback

The stock market has been on a tear for more than a month now, and so it's not unreasonable to see major market benchmarks taking a pause coming into a new week. Stock indexes were mostly flat at

What are some unstoppable stocks to buy right now? Three Fool.com contributors think they've found three stocks that qualify -- and they're all in the healthcare sector. Here's why they picked

Change the narrative: That's been a classic strategy for businesses facing stiff challenges. And it's a strategy that AbbVie (NYSE: ABBV) appears to have pulled off successfully in recent days.

Vertex Pharmaceuticals (NASDAQ: VRTX) has built a billion-dollar cystic fibrosis (CF) treatment empire, but investors have been looking for something more. They've hoped to see the company broaden